Understanding how cancer genomes evolve rapidly
Mechanisms Driving the Rapid Evolution of Cancer Genomes
This study is looking into how certain changes in cancer cells happen quickly during cell division, which can lead to more aggressive cancer growth, and it aims to help us understand these changes better so we can improve treatments for people with cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10981027 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the rapid evolution of cancer genomes, focusing on a process called chromothripsis, which leads to significant chromosome rearrangements during cell division. By utilizing advanced single-cell genomics technology, the researchers aim to uncover how these genetic changes occur and their implications for cancer development. The study will explore the role of nuclear structures that can cause extensive DNA damage, ultimately affecting how cancer cells grow and divide. This research could provide insights into the fundamental processes that drive cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with aggressive or treatment-resistant cancers that exhibit rapid genomic changes.
Not a fit: Patients with stable, non-aggressive cancers or those who do not exhibit significant genomic alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer treatment by targeting the mechanisms that drive genomic instability.
How similar studies have performed: Previous research has shown promising results in understanding chromosomal instability in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Pellman, David S — Dana-Farber Cancer Inst
- Study coordinator: Pellman, David S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.